ValuEngine cut shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) from a hold rating to a sell rating in a research report report published on Monday.

Several other equities research analysts have also recently weighed in on the company. BMO Capital Markets boosted their price objective on Protagonist Therapeutics from $34.00 to $45.00 and gave the stock an outperform rating in a research note on Wednesday, May 31st. BTIG Research initiated coverage on Protagonist Therapeutics in a research note on Friday, July 21st. They set a buy rating and a $36.00 price objective on the stock. Finally, Zacks Investment Research raised Protagonist Therapeutics from a sell rating to a hold rating in a research note on Wednesday, August 2nd.

Shares of Protagonist Therapeutics (NASDAQ:PTGX) opened at 14.61 on Monday. Protagonist Therapeutics has a one year low of $8.00 and a one year high of $26.36. The company’s 50-day moving average price is $13.28 and its 200 day moving average price is $12.07. The stock’s market capitalization is $246.94 million.

Protagonist Therapeutics (NASDAQ:PTGX) last issued its quarterly earnings data on Tuesday, August 8th. The company reported ($0.89) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.70).

TRADEMARK VIOLATION NOTICE: “Protagonist Therapeutics, Inc. (PTGX) Cut to Sell at ValuEngine” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/09/14/protagonist-therapeutics-inc-ptgx-cut-to-sell-at-valuengine.html.

In other news, insider David Y. Liu sold 3,500 shares of the company’s stock in a transaction that occurred on Monday, August 28th. The stock was sold at an average price of $15.00, for a total transaction of $52,500.00. Following the transaction, the insider now owns 5,500 shares of the company’s stock, valued at $82,500. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Richard S. Shames sold 1,512 shares of the company’s stock in a transaction that occurred on Tuesday, August 29th. The shares were sold at an average price of $17.00, for a total value of $25,704.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 12,199 shares of company stock worth $175,345.

Several institutional investors and hedge funds have recently added to or reduced their stakes in PTGX. Senzar Asset Management LLC bought a new position in shares of Protagonist Therapeutics during the second quarter valued at approximately $3,094,000. State Street Corp grew its stake in shares of Protagonist Therapeutics by 20.9% during the second quarter. State Street Corp now owns 112,474 shares of the company’s stock valued at $1,270,000 after buying an additional 19,411 shares during the last quarter. Northern Trust Corp grew its stake in shares of Protagonist Therapeutics by 24.0% during the second quarter. Northern Trust Corp now owns 98,825 shares of the company’s stock valued at $1,118,000 after buying an additional 19,159 shares during the last quarter. Northern Capital Management LLC bought a new position in shares of Protagonist Therapeutics during the second quarter valued at approximately $188,000. Finally, Vanguard Group Inc. grew its stake in shares of Protagonist Therapeutics by 3.8% during the second quarter. Vanguard Group Inc. now owns 325,395 shares of the company’s stock valued at $3,680,000 after buying an additional 11,881 shares during the last quarter. 48.19% of the stock is currently owned by hedge funds and other institutional investors.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Stock Ratings for Protagonist Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics Inc. and related stocks with our FREE daily email newsletter.